QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity

Expert Review of Molecular Diagnostics

Volumn 11, Issue 1, 2011, Pages 17-25

  Giulieri, Stefano ^a   Manuel, Oriol ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

cellular immunity; CMV; IFN release assay; immunocompromised host

Indexed keywords

GAMMA INTERFERON; VIRUS ANTIGEN;

CELLULAR IMMUNITY; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; IMMUNOCOMPROMISED PATIENT; NONHUMAN; ORGAN TRANSPLANTATION; QUANTIFERON CMV ASSAY; REVIEW; SENSITIVITY AND SPECIFICITY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNITY, CELLULAR; IMMUNOCOMPROMISED HOST; INTERFERON-GAMMA; MOLECULAR DIAGNOSTIC TECHNIQUES; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION IMMUNOLOGY;

EID: 78650565328     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.109     Document Type: Review

References (65)

1. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol. Blood Marrow Transplant. 9(9), 543-558 (2003).
2. Hakki M, Boeckh M, Ljungman P. Cytomegalovirus infection after stem cell transplantation. In: Transplant Infections (3rd Edition). Bowden RA, Ljungman P, Snydman D (Eds). Lippincott Williams & Wilkins, PA, USA 311-327 (2010).
3. Razonable RR, Limaye AP. Cytomegalovirus infection after solid organ transplantation. In: Transplant Infections (3rd Edition). Bowden RA, Ljungman P, Snydman D (Eds). Lippincott Williams & Wilkins, PA, USA 328-361 (2010).
4. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am. J. Transplant. 6(2), 262-274 (2006).
5. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am. J. Transplant. 9(Suppl. 4), S78-S86 (2009).
6. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med. 340(19), 1462-1470 (1999). (Pubitemid 29220545)
7. Bando K, Paradis IL, Similo S et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J. Thorac. Cardiovasc. Surg. 110(1), 4-13 (1995).
8. George MJ, Snydman DR, Werner BG et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am. J. Med. 103(2), 106-113 (1997).
9. Cantoni N, Hirsch HH, Khanna N et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol. Blood Marrow Transplant. 16(9), 1309-1314 (2010).
10. Deayton JR, Wilson P, Sabin CA et al. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS 14(9), 1163-1170 (2000).
11. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am. J. Transplant. 4(6), 928-936 (2004).
12. Corales R, Chua J, Mawhorter S et al. Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon? Transpl. Infect. Dis. 2(3), 133-139 (2000).
13. Doron S, Ruthazer R, Werner BG, Rabson A, Snydman DR. Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes. Transplantation 81(5), 697-703 (2006).
14. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103(6), 2003-2008 (2004).
15. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann. Intern. Med. 143(12), 870-880 (2005).
16. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am. J. Transplant. 8(5), 975-983 (2008).
17. Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am. J. Transplant. 8(1), 69-77 (2008).
18. Kotton CN, Kumar D, Caliendo AM et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89(7), 779-795 (2010).
19. Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation. Am. J. Transplant. 8(1), 158-161 (2008).
20. Manuel O, Venetz JP, Fellay J et al. Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/ mycophenolate-based regimen in kidney transplantation. Swiss Med. Wkly 137(47-48), 669-676 (2007).
21. Wasserfallen JB, Kast-Bruckner M, Manuel O, Venetz JP, Meylan PR, Pascual M. Cost-effectiveness of a new combined immunosuppressive and anti-infectious regimen in kidney transplantation. Int. J. Technol. Assess. Health Care 24(3), 312-317 (2008).
22. Humar A, Lebranchu Y, Vincenti F et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am. J. Transplant. 10(5), 1228-1237 (2010).
23. Mitsani D, Nguyen MH, Kwak EJ et al. Cytomegalovirus disease among donorpositive/ recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis. J. Heart Lung Transplant. 29(9), 1014-1020 (2010).
24. Meylan PR, Manuel O. Late-onset cytomegalovirus disease in patients with solid organ transplant. Curr. Opin. Infect. Dis. 20(4), 412-418 (2007).
25. Lamoth F, Manuel O, Venetz JP, Faouzi M, Meylan P, Pascual M. What is the impact of late-onset cytomegalovirus disease after valganciclovir prophylaxis in kidney transplantation? Transplantation 86(9), 1323-1324 (2008).
26. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 4(4), 611-620 (2004).
27. Arthurs SK, Eid AJ, Pedersen RA et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin. Infect. Dis. 46(6), 840-846 (2008).
28. Limaye AP, Bakthavatsalam R, Kim HW et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 81(12), 1645-1652 (2006).
29. Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant. 42(Suppl. 1), S70-S72 (2008).
30. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113(23), 5711-5719 (2009).
31. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin. Microbiol. Rev. 22(1), 76-98 (2009).
32. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis. 4(12), 725-738 (2004).
33. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78(5), 1373-1380 (1991).
34. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)- specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83(7), 1971-1979 (1994).
35. Crough T, Fazou C, Weiss J et al. Symptomatic and asymptomatic viral recrudescence in solid-organ transplant recipients and its relationship with the antigen-specific CD8+ T-cell response. J. Virol. 81(20), 11538-11542 (2007).
36. Ljungman P, Aschan J, Azinge JN et al. Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. Br. J. Haematol. 83(1), 118-124 (1993).
37. Hebart H, Daginik S, Stevanovic S et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-genzyme- linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 99(10), 3830-3837 (2002).
38. Sester U, Gartner BC, Wilkens H et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am. J. Transplant. 5(6), 1483-1489 (2005).
39. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann. Intern. Med. 124(7), 633-642 (1996).
40. Salmon-Ceron D, Mazeron MC, Chaput S et al. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. AIDS 14(8), 1041-1049 (2000).
41. Steininger C, Puchhammer-Stockl E, Popow-Kraupp T. Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART). J. Clin. Virol. 37(1), 1-9 (2006).
42. Humar A, Paya C, Pescovitz MD et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am. J. Transplant. 4(4), 644-649 (2004).
43. Humar A, Mazzulli T, Moussa G et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/Rtransplant recipients. Am. J. Transplant. 5(5), 1065-1070 (2005).
44. Danziger-Isakov L, Heeger PS. Clinical utility of measuring T-cell immunity to CMV in transplant recipients. Am. J. Transplant. 9(5), 987-988 (2009).
45. Walker S, Fazou C, Crough T et al. Ex vivo monitoring of human cytomegalovirusspecific CD8+ T-cell responses using QuantiFERON-CMV. Transpl. Infect. Dis. 9(2), 165-170 (2007).
46. Kumar D, Chernenko S, Moussa G et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am. J. Transplant. 9(5), 1214-1222 (2009).
47. Fleming T, Dunne J, Crowley B. Ex vivo monitoring of human cytomegalovirusspecific CD8+ T-cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital. J. Med. Virol. 82(3), 433-440 (2010).
48. Westall GP, Mifsud NA, Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMVspecific CD8+ T-cell immunity. Am. J. Transplant. 8(8), 1749-1754 (2008).
49. Singh KP, Howard JL, Wild SP, Jones SL, Hoy J, Lewin SR. Human cytomegalovirus (CMV)-specific CD8+ T cell responses are reduced in HIV-infected individuals with a history of CMV disease despite CD4+ T cell recovery. Clin. Immunol. 124(2), 200-206 (2007).
50. Harari A, Vallelian F, Meylan PR, Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J. Immunol. 174(2), 1037-1045 (2005).
51. Eid AJ, Brown RA, Arthurs SK et al. A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection. Transpl. Int. 23(5), 506-513 (2010).
52. Egli A, Binet I, Binggeli S et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J. Transl. Med. 6, 29 (2008).
53. Sester M, Sester U, Gartner B et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 71(9), 1287-1294 (2001).
54. Bunde T, Kirchner A, Hoffmeister B et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J. Exp. Med. 201(7), 1031-1036 (2005).
55. Gerna G, Lilleri D, Fornara C et al. Monitoring of human cytomegalovirusspecific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am. J. Transplant. 6(10), 2356-2364 (2006).
56. Radha R, Jordan S, Puliyanda D et al. Cellular immune responses to cytomegalovirus in renal transplant recipients. Am. J. Transplant. 5(1), 110-117 (2005). (Pubitemid 40095134)
57. Shlobin OA, West EE, Lechtzin N et al. Persistent cytomegalovirus- specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients. J. Immunol. 176(4), 2625-2634 (2006).
58. Jacobson MA, Maecker HT, Orr PL et al. Results of a cytomegalovirus (CMV)- specific CD8+/interferon-g+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis. J. Infect. Dis. 189(8), 1362-1373 (2004).
59. Weinberg A, Wohl DA, MaWhinney S et al. Cytomegalovirus-specific IFN-g production is associated with protection against cytomegalovirus reactivation in HIV-infected patients on highly active antiretroviral therapy. AIDS 17(17), 2445-2450 (2003).
60. Mattes FM, Vargas A, Kopycinski J et al. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am. J. Transplant. 8(5), 990-999 (2008).
61. Weinberg A, Tierney C, Kendall MA et al. Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy. J. Infect. Dis. 193(4), 488-493 (2006).
62. Gratama JW, Boeckh M, Nakamura R et al. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood 116(10), 1655-1662 (2010).
63. Crough T, Fazou C, Weiss J et al. Symptomatic and asymptomatic viral recrudescence in solid-organ transplant recipients and its relationship with the antigen-specific CD8+ T-cell response. J. Virol. 81(20), 11538-11542 (2007).
64. Cervera C, Lozano F, Saval N et al. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation 83(11), 1493-1500 (2007).
65. Manuel O, Pascual M, Trendelenburg M, Meylan PR. Association between mannosebinding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation 83(3), 359-362 (2007)